FDA Inspection 1102650 — Rentschler Biopharma SE
The FDA completed an inspection of Rentschler Biopharma SE on Aug 9, 2019 in Laupheim. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 9, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Laupheim (Germany)